BioGene Therapeutics
BioGene Therapeutics is a Texas-based, pre-clinical life sciences company developing brain-targeted gene therapies for diabetes and obesity using a proprietary bioresponsive lipid nanoparticle platform, Smart-siRNAs against PTP1B, and a Sol-Gel nose-to-brain delivery system. It serves patients and providers in metabolic disease via future licensing or direct commercialization.
- Company typePublic
- Founded2024
- HeadquartersTexas, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What BioGene Therapeutics does
BioGene Therapeutics Inc. is a Texas-based life sciences company, incorporated in 2024 and headquartered at 5900 Balcones Drive STE 100 in Austin, that is developing gene therapies for diabetes and obesity. The company was established as a wholly-owned subsidiary of PreveCeutical Medical Inc. (CSE: PREV) and underwent a spin-off via a plan of arrangement effective November 2025, in which 12 million BioGene shares were distributed to PreveCeutical shareholders. BioGene's core technology portfolio comprises three integrated platform components: a patented Bioresponsive Lipid Nanoparticle (bLNP) non-viral vector platform (US Patent #11,566,044, granted March 31, 2023) with redox-potential sensitive intracellular gene-cargo release; a Sol-Gel nose-to-brain drug delivery system that bypasses the blood-brain barrier via olfactory cleft targeting; and Smart-siRNAs that selectively target PTP1B messenger RNA to reinstate normal insulin and leptin signaling. The lead program combines these platforms into a dual mechanism gene therapy designed to inhibit PTP1B in the brain for treatment of metabolic disorders.
BioGene's business model is currently pre-revenue and pre-commercial. The company has not commercialized any products, has no publicly disclosed pricing, and is funded to date primarily by the USD$1,353,227 IP acquisition consideration received from PreveCeutical. Future revenue mechanics are described as likely combinations of licensing agreements with major pharmaceutical partners and direct commercialization upon regulatory approval. The customer base today consists of researchers and academic collaborators rather than paying customers; end-patient segments are defined as individuals with diabetes, obesity, and related metabolic conditions, as well as the endocrinologists, primary care physicians, and metabolic disease specialists who treat them. The company leverages Australia's 43.5% R&D tax cashback incentive through its wholly-owned subsidiary BioGene Australia (Queensland), positioning the geographic footprint across North America (US) and Oceania (Australia).
The go-to-market motion is investor- and partnership-led: BioGene operates a corporate website with an investor center, distributes quarterly investor presentations, issues news releases on board and pipeline milestones, and participated in the 43rd JP Morgan Healthcare Conference in January 2025 with leadership meetings aimed at potential pharmaceutical partnerships or licensing transactions. The company is led by Chairman and CEO Stephen Van Deventer (also Chairman/CEO of PreveCeutical), President Dr. Mariya Georgieva (ex-AstraZeneca Precision Medicine R&D), CSO Dr. Linnea Olofsson, CTO Dr. Francis Tavares (ex-GSK), CRO and Scientific Founder Dr. Harry Parekh (University of Queensland), with an independent board and scientific advisory board including senior figures from Ultragenyx, Sarepta, Vertex, Genentech, Stoke Therapeutics, and the University of Aberdeen.
BioGene Therapeutics firmographics
Firmographics- Name
- BioGene Therapeutics
- Legal name
- BioGene Therapeutics Inc.
- Website
- https://biogenetherapeutics.com
- Company type
- Public
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- BioGene Therapeutics is a Texas-based, pre-clinical life sciences company developing brain-targeted gene therapies for diabetes and obesity using a proprietary bioresponsive lipid nanoparticle platform, Smart-siRNAs against PTP1B, and a Sol-Gel nose-to-brain delivery system. It serves patients and providers in metabolic disease via future licensing or direct commercialization.
- Ownership category
- akta.pro rank
BioGene Therapeutics industry classification
Industry- Product category
- Metabolic Disease Gene Therapy
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Cardiometabolic & Other Systemic Gene Therapies (HLAAACAI)
- akta.pro secondary industries
- siRNA Therapeutics (gene silencing) (HLAAADAB), Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery) (HLAAACAL)
Keywords
Where BioGene Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Texas
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
BioGene Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Future Therapeutic Product Sales: Pre-revenue company planning to commercialize gene therapies for diabetes and obesity. Expected to pursue licensing partnerships or direct commercialization upon regulatory approval.
Go-to-market motion1 record
Marketing channels5 records
BioGene Therapeutics product offering
Product offeringCore offering
BioGene Therapeutics develops proprietary gene therapy delivery platforms and therapeutic candidates targeting metabolic disorders, primarily diabetes and obesity. Its core technology stack combines Bioresponsive Lipid Nanoparticles (bLNPs) carrying metabolically stabilized Smart-siRNAs that inhibit PTP1B, delivered directly to the brain via a Sol-Gel nasal spray that bypasses the blood-brain barrier. The company is pre-revenue and advancing its lead Dual Gene Therapy Program through preclinical and research stages with the intent to license or commercialize following regulatory approval.
Product overview
BioGene Therapeutics is developing a portfolio of modular gene therapy platform technologies for metabolic health. The core offerings include: the Sol-Gel Nose-to-Brain Delivery Platform for non-invasive direct brain administration; Bioresponsive Lipid Nanoparticles (bLNP) serving as the proprietary non-viral gene cargo carrier with patented intracellular release mechanisms; and Smart-siRNAs targeting PTP1B for diabetes and obesity treatment. These platforms integrate as a dual gene therapy system, where Smart-siRNA cargo is delivered via bLNPs through the Sol-Gel nasal spray to achieve brain-specific PTP1B inhibition.
Differentiator
Problem solved
Functional benefit
Products and services
- Sol-Gel Nose-to-Brain Delivery Platform A patient-friendly nasal spray delivery platform that bypasses the blood-brain barrier by targeting the olfactory cleft, enabling direct nose-to-brain delivery of therapeutic payloads including siRNA, monoclonal antibodies, Fab fragments, and small molecules.
- Bioresponsive Lipid Nanoparticles (bLNP) A patented non-viral vector platform that protects genetic cargo from nuclease degradation and enables controlled intracellular release via redox-potential sensitive mechanisms, with anti-inflammatory degradation properties. Compatible with siRNA, mRNA, and pDNA cargo.
- Smart-siRNAs (PTP1B Targeting) Selective, metabolically stabilized small interfering RNAs engineered to target PTP1B messenger RNA, inhibiting protein production and reinstating normal insulin and leptin signaling for treatment of diabetes and obesity.
- Dual Gene Therapy Program for Diabetes and Obesity Therapeutic program combining Smart-siRNAs with bLNP vectors delivered via the Sol-Gel platform to address both diabetes and obesity through brain-directed PTP1B inhibition, aiming to restore metabolic functions rather than manage symptoms.
Quantifiable outcome
- Preclinical studies show complete protection against obesity and insulin resistance when PTP1B is deleted exclusively in the brain, even when fed high-fat obesity-inducing diet
Companies that use BioGene Therapeutics
Customer profileSegments2 records
Ideal customer profiles2 records
BioGene Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
BioGene Therapeutics partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered minor and core.
- UltragenyxminorDr. Deepak Sampath, who joined BioGene's Board of Directors, currently serves as Senior Vice President and Head of Research at Ultragenyx. This represents a board-level connection rather than a formal corporate partnership.
- PreveCeutical Medical Inc.coreBioGene Therapeutics was established as a wholly-owned subsidiary of PreveCeutical Medical Inc. On October 30, 2024, a definitive agreement was signed to transfer intellectual property assets including the Sol-Gel and bLNP platforms to BioGene for USD$1,353,227 (USD$500,000 cash + 16 million shares). A plan of arrangement effective November 2025 resulted in distribution of 12 million BioGene shares to PreveCeutical shareholders, creating two focused entities.
- UniQuest Pty LtdcorePreveCeutical Australia engaged UniQuest Pty Ltd for ongoing research program. Background IP includes bioreducible amino acid derivatives, bioreducible peptide dendrimers, and methods/know-how for producing such derivatives developed at the University of Queensland under Dr. Harendra Parekh's research group. This IP was acquired by BioGene as part of the asset purchase.
- University of QueenslandcoreBioGene's scientific founder Dr. Harry Parekh leads the Drug/Gene Delivery Group at the School of Pharmacy & Pharmaceutical Sciences at the University of Queensland, Australia. The research collaboration focused on drug/gene delivery platform systems for cancer, obesity-diabetes, macular disease, and infectious disease. BioGene Australia leverages Australia's 43.5% R&D tax cashback incentive.
Scale indicators3 records
Recent moves8 records
Expansion highlights5 records
BioGene Therapeutics competitors and assessment
Company assessmentBroad incumbents
- Alnylam Pharmaceuticals: Alnylam is the established leader in siRNA therapeutics with multiple approved products and broad pipeline across metabolic, hepatic, and rare diseases. Directly comparable to BioGene in siRNA modality and LNP delivery approach.
- Sarepta Therapeutics: Sarepta is a leading gene therapy company with multiple approved AAV-delivered products. Comparable as a broad gene therapy incumbent with platform-based approach; Ty Howton has prior Sarepta experience.
- Novo Nordisk: Novo Nordisk dominates the GLP-1 RA market (Ozempic, Wegovy) and acquired Dicerna for siRNA capabilities. Broad incumbent competing for the same metabolic disease TAM BioGene targets.
- Eli Lilly: Eli Lilly leads the GLP-1 market (Mounjaro, Zepbound) and is investing heavily in next-gen metabolic therapeutics including gene therapy. Broad incumbent and dominant competitor in metabolic disease space.
Direct peers
- Arrowhead Pharmaceuticals: Arrowhead develops RNAi-based therapeutics using proprietary LNP and TRiM delivery platforms for metabolic and other diseases. Highly comparable to BioGene on siRNA platform and metabolic/obesity indication focus.
- Voyager Therapeutics: Voyager focuses on CNS-targeted gene therapy with novel capsids and delivery platforms. Comparable to BioGene's brain-directed delivery approach for neurological and metabolic disease.
- Lexeo Therapeutics: Lexeo is a clinical-stage gene therapy company with programs in cardiac and CNS indications using AAV and non-viral delivery. Comparable on platform-technology gene therapy model and CNS targeting.
- Solid Biosciences: Solid Biosciences develops gene therapies for neuromuscular and cardiac diseases with non-viral delivery approaches. Board member Ty Howton is COO; comparable on gene therapy platform model targeting severe diseases.
Emerging players
- Wave Life Sciences: Wave is developing RNA-based medicines including siRNA and antisense oligonucleotides with CNS-penetrant delivery programs. Comparable on RNA modality and CNS targeting strategy.
- Fractyl Health: Fractyl is developing disease-modifying therapies for metabolic diseases including obesity and T2D, with a gene therapy program (Rejuva). Direct competitor in the metabolic gene therapy space where BioGene is focused.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
BioGene Therapeutics social profiles
Digital presenceBioGene Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
BioGene Therapeutics leadership team
Management profileNumber of profiles
Profiles15 records
BioGene Therapeutics subsidiaries and ownership
Company hierarchySubsidiaries1 record
BioGene Therapeutics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BioGene Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BioGene Therapeutics
What does BioGene Therapeutics do?
BioGene Therapeutics develops proprietary gene therapy delivery platforms and therapeutic candidates targeting metabolic disorders, primarily diabetes and obesity. Its core technology stack combines Bioresponsive Lipid Nanoparticles (bLNPs) carrying metabolically stabilized Smart-siRNAs that inhibit PTP1B, delivered directly to the brain via a Sol-Gel nasal spray that bypasses the blood-brain barrier. The company is pre-revenue and advancing its lead Dual Gene Therapy Program through preclinical and research stages with the intent to license or commercialize following regulatory approval.
Is BioGene Therapeutics a public or private company?
BioGene Therapeutics is a public company. It is classified as public and is currently operating.
When was BioGene Therapeutics founded?
BioGene Therapeutics was founded in 2024. It employs 1 to 10 people.
Where is BioGene Therapeutics based?
BioGene Therapeutics is headquartered in Texas, United States, in the North America region.
How does BioGene Therapeutics make money?
One revenue line is on record: future Therapeutic Product Sales.
Who are BioGene Therapeutics's main competitors?
Broad incumbents on record are Alnylam Pharmaceuticals, Sarepta Therapeutics, Novo Nordisk and Eli Lilly. Direct peers are Arrowhead Pharmaceuticals, Voyager Therapeutics, Lexeo Therapeutics and Solid Biosciences. Emerging players are Wave Life Sciences and Fractyl Health.
Does BioGene Therapeutics have an API?
No public API is recorded for BioGene Therapeutics.
What industry is BioGene Therapeutics in?
BioGene Therapeutics's product category is Metabolic Disease Gene Therapy. Its primary akta.pro industry code is HLAAACAI, Cardiometabolic & Other Systemic Gene Therapies, with a secondary code of HLAAADAB, siRNA Therapeutics (gene silencing). Its NAICS code is 541714 and its SIC code is 2836.